Prohost Biotech submits:In the news, Cytokinetics (CYTK) announced that, in the first half of 2011, the company and Amgen (AMGN) have agreed to initiate a Phase IIb clinical trial of an intravenous formulation of omecamtiv mecarbil for patients with left ventricular systolic dysfunction hosp
WASHINGTON (AP) -- Scientists for the Food and Drug Administration say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects....
WASHINGTON — Scientists for the Food and Drug Administration say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects.
By Bryce Istvan:Xgeva, part of the Denosumab family, is Amgen’s (AMGN) latest bone related drug. Its current indication is for the treatment of skeletal related events (SREs) caused by bone metastases in all cancers excluding multiple myelomas.
Amgen Inc. (AMGN) received a boost recently when the company announced positive results from a pivotal head-to-head phase III study that was conducted with Amgen’s main pipeline candidate, denosumab.
M.E. Garza submits:
BioSante Pharmaceuticals (BPAX) announced Monday that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been lifted by FDA, but will that news be enough to get investors to buy-in and hold on to shares?